Literature DB >> 12437641

Anti-myeloma activity of natural killer lymphocytes.

Christoph Frohn1, Maike Höppner, Peter Schlenke, Holger Kirchner, Petra Koritke, Jürgen Luhm.   

Abstract

Natural killer (NK) cells are assumed to contribute to a graft-versus-leukaemia effect. In vitro experiments have shown that many leukaemic cells are NK-cell sensitive. Nevertheless, no data concerning the influence of purified NK cells on malignant myeloma (MM) cells exist. We co-incubated NK cells with three different MM cell lines and fresh bone marrow samples of nine MM patients. The proportion of vital MM cells was determined before and after co-cultivation by a flow-cytometry-based assay. All MM cells tested, with the exception of one cell line (NCI H929), were susceptible to a NK-cell attack even without exogenous interleukin 2 (IL-2). The mean killing of the native MM samples was 23.1 +/- 5.4% and 34.5 +/- 6.5% at 10:1 and 20:1 effector:target ratio respectively, This corresponded to about 2/3 of those values obtained with the highly sensitive line K562. In contrast, CD34-positive haematopoietic stem cells as well as peripheral mononuclear cells were completely resistant under similar experimental conditions (1.3% killing). To elucidate the underlying triggering mechanisms, we measured human leucocyte antigen (HLA)-class I expression of the MM cells. No evidence for HLA loss, which could have explained the NK-cell recognition if it occurred, was demonstrated. These findings may contribute to the understanding of in vivo NK-cell activation and encourage clinical applications of NK cells for MM patients.

Entities:  

Mesh:

Year:  2002        PMID: 12437641     DOI: 10.1046/j.1365-2141.2002.03879.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  31 in total

1.  Natural killer cell lines preferentially kill clonogenic multiple myeloma cells and decrease myeloma engraftment in a bioluminescent xenograft mouse model.

Authors:  Brenna E Swift; Brent A Williams; Yoko Kosaka; Xing-Hua Wang; Jeffrey A Medin; Sowmya Viswanathan; Joaquin Martinez-Lopez; Armand Keating
Journal:  Haematologica       Date:  2012-01-22       Impact factor: 9.941

Review 2.  MGUS to myeloma: a mysterious gammopathy of underexplored significance.

Authors:  Madhav V Dhodapkar
Journal:  Blood       Date:  2016-10-13       Impact factor: 22.113

3.  GRP78-directed immunotherapy in relapsed or refractory multiple myeloma - results from a phase 1 trial with the monoclonal immunoglobulin M antibody PAT-SM6.

Authors:  Leo Rasche; Johannes Duell; Inês C Castro; Valentina Dubljevic; Manik Chatterjee; Stefan Knop; Frank Hensel; Andreas Rosenwald; Hermann Einsele; Max S Topp; Stephanie Brändlein
Journal:  Haematologica       Date:  2015-01-30       Impact factor: 9.941

4.  Treatment of multiple myeloma with adoptively transferred chimeric NKG2D receptor-expressing T cells.

Authors:  A Barber; K R Meehan; C L Sentman
Journal:  Gene Ther       Date:  2011-01-06       Impact factor: 5.250

5.  IPH2101, a novel anti-inhibitory KIR antibody, and lenalidomide combine to enhance the natural killer cell versus multiple myeloma effect.

Authors:  Don M Benson; Courtney E Bakan; Shuhong Zhang; Shauna M Collins; Jing Liang; Shivani Srivastava; Craig C Hofmeister; Yvonne Efebera; Pascale Andre; Francois Romagne; Mathieu Bléry; Cécile Bonnafous; Jianying Zhang; David Clever; Michael A Caligiuri; Sherif S Farag
Journal:  Blood       Date:  2011-10-26       Impact factor: 22.113

6.  Phase I study of cord blood-derived natural killer cells combined with autologous stem cell transplantation in multiple myeloma.

Authors:  Nina Shah; Li Li; Jessica McCarty; Indreshpal Kaur; Eric Yvon; Hila Shaim; Muharrem Muftuoglu; Enli Liu; Robert Z Orlowski; Laurence Cooper; Dean Lee; Simrit Parmar; Kai Cao; Catherine Sobieiski; Rima Saliba; Chitra Hosing; Sairah Ahmed; Yago Nieto; Qaiser Bashir; Krina Patel; Catherine Bollard; Muzaffar Qazilbash; Richard Champlin; Katy Rezvani; Elizabeth J Shpall
Journal:  Br J Haematol       Date:  2017-03-14       Impact factor: 6.998

7.  Infusion of haplo-identical killer immunoglobulin-like receptor ligand mismatched NK cells for relapsed myeloma in the setting of autologous stem cell transplantation.

Authors:  Jumei Shi; Guido Tricot; Susann Szmania; Nancy Rosen; Tarun K Garg; Priyangi A Malaviarachchi; Amberly Moreno; Bo Dupont; Katharine C Hsu; Lee Ann Baxter-Lowe; Michele Cottler-Fox; John D Shaughnessy; Bart Barlogie; Frits van Rhee
Journal:  Br J Haematol       Date:  2008-10-16       Impact factor: 6.998

Review 8.  Biology and clinical impact of human natural killer cells.

Authors:  Sherif S Farag; Jeffrey B VanDeusen; Todd A Fehniger; Michael A Caligiuri
Journal:  Int J Hematol       Date:  2003-07       Impact factor: 2.490

9.  Early hematopoietic zinc finger protein prevents tumor cell recognition by natural killer cells.

Authors:  Rosanna La Rocca; Mariateresa Fulciniti; Tadepally Lakshmikanth; Maria Mesuraca; Talib Hassan Ali; Valerio Mazzei; Nicola Amodio; Lucio Catalano; Bruno Rotoli; Ouathek Ouerfelli; Michele Grieco; Elio Gulletta; Heather M Bond; Giovanni Morrone; Soldano Ferrone; Ennio Carbone
Journal:  J Immunol       Date:  2009-04-15       Impact factor: 5.422

Review 10.  Immune responses in multiple myeloma: role of the natural immune surveillance and potential of immunotherapies.

Authors:  Camille Guillerey; Kyohei Nakamura; Slavica Vuckovic; Geoffrey R Hill; Mark J Smyth
Journal:  Cell Mol Life Sci       Date:  2016-01-22       Impact factor: 9.261

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.